Inhibition of tumor suppressor p53 preserves glycation-serum induced pancreatic beta-cell demise
- 346 Downloads
Tumor suppressor p53 is a transcriptional factor that determines cell fate in response to multiple stressors, such as oxidative stress and endoplasmic reticulum stress, in the majority of cells. However, its role in pancreatic beta cells is not well documented. Our previous research has revealed that glycation-serum (GS) induced pancreatic beta-cell demise through the AGEs-RAGE pathway. In the present study, we investigated the role of p53 in GS-related beta-cell demise. Using pancreatic islets beta-cell line INS-1 cells, we found that with GS treatment, the transcriptional activity of p53 was significantly evoked due to the increased amount of nuclear p53 protein. Resveratrol (RSV) was capable of further enhancing this transcriptional ability and consequently increased the population of dead beta cells under GS exposure. In contrast, inhibiting this transcriptional activity via p53 interference greatly protected beta cells from the damage provoked by GS, as well as damage strengthened by RSV. However, the pharmacological activation of PPARγ with troglitazone (TRO) only suppressed GS-induced, not RSV-induced, p53 activity. Moreover, the activation of PPARγ greatly preserved beta cells from GS-induced death. This protective effect recurred due to improved mitochondrial function with Bcl2 overexpression. Further, p53 activation could induce cellular apoptosis in primary rat islets. Our findings explore the broader role of p53 in regulating pancreatic beta-cell demise in the presence of GS and may provide a therapeutic target for the treatment and prevention of diabetes.
Keywordsp53 Glycation-serum Pancreatic beta-cell demise Diabetes
This study was supported by research grants from (1) the National Natural Science Foundation of China (81420108007) and the National Basic Research Program of China (973 Program, 2012CB524903) to XH, (2) the National Natural Science Foundation of China (81200559) to YZ, and (3) the National Natural Science Foundation of China (81472989) to HZ. XH is a Fellow at the Collaborative Innovation Center for Cardiovascular Disease Translational Medicine.
Compliance with ethical standards
Conflict of interest
The authors took part in the conception and design of the study, as well as either drafting or critically revising the manuscript. The authors have approved the final version of the manuscript.
- 11.W. Cai, M. Ramdas, L. Zhu, X. Chen, G.E. Striker, H. Vlassara, Oral advanced glycation end products (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc. Natl. Acad. Sci. USA 109, 15888–15893 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
- 14.J. Uribarri, W. Cai, M. Ramdas, S. Goodman, R. Pyzik, X. Chen, L. Zhu, G.E. Striker, H. Vlassara, Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 34, 1610–1616 (2011)CrossRefPubMedPubMedCentralGoogle Scholar
- 17.A. Puddu, R. Sanguineti, A. Durante, A. Nencioni, F. Mach, F. Montecucco, G.L. Viviani, Glucagon-like peptide-1 triggers protective pathways in pancreatic beta-cells exposed to glycated serum. Mediat. Inflamm. 2013, 317120 (2013)Google Scholar
- 22.S.E. Thomas, E. Malzer, A. Ordonez, L.E. Dalton, E.F. van ‘t Wout, E. Liniker, D.C. Crowther, D.A. Lomas, S.J. Marciniak, p53 and translation attenuation regulate distinct cell cycle checkpoints during endoplasmic reticulum (ER) stress. J. Biol. Chem. 288, 7606–7617 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Z. Zhao, C. Zhao, X.H. Zhang, F. Zheng, W. Cai, H. Vlassara, Z.A. Ma, Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology 150, 2569–2576 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
- 33.M.T. Coughlan, F.Y. Yap, D.C. Tong, S. Andrikopoulos, A. Gasser, V. Thallas-Bonke, D.E. Webster, J. Miyazaki, T.W. Kay, R.M. Slattery, D.M. Kaye, B.G. Drew, B.A. Kingwell, S. Fourlanos, P.H. Groop, L.C. Harrison, M. Knip, J.M. Forbes, Advanced glycation end products are direct modulators of beta-cell function. Diabetes 60, 2523–2532 (2011)CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Ge QM, Dong Y, Su Q. Effects of glucose and advanced glycation end products on oxidative stress in MIN6 cells. Cell Mol Biol (Noisy-le-grand). 2010; 56 Suppl: OL1231-8Google Scholar
- 37.K.C. Lan, C.Y. Chiu, C.W. Kao, K.H. Huang, C.C. Wang, K.T. Huang, K.S. Tsai, M.L. Sheu, S.H. Liu, Advanced glycation end-products induce apoptosis in pancreatic islet endothelial cells via NF-kappaB-activated cyclooxygenase-2/prostaglandin E2 up-regulation. PLoS ONE 10, e0124418 (2015)CrossRefPubMedPubMedCentralGoogle Scholar
- 39.C. Arous, P.G. Ferreira, E.T. Dermitzakis, P.A. Halban, Short term exposure of beta cells to low concentrations of interleukin-1beta improves insulin secretion through focal adhesion and actin remodeling and regulation of gene expression. J. Biol. Chem. 290, 6653–6669 (2015)CrossRefPubMedPubMedCentralGoogle Scholar
- 43.K. Maedler, P. Sergeev, F. Ris, J. Oberholzer, H.I. Joller-Jemelka, G.A. Spinas, N. Kaiser, P.A. Halban, M.Y. Donath, Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110, 851–860 (2002)CrossRefPubMedPubMedCentralGoogle Scholar
- 47.S. Tornovsky-Babeay, D. Dadon, O. Ziv, E. Tzipilevich, T. Kadosh, R. Schyr-Ben Haroush, A. Hija, M. Stolovich-Rain, J. Furth-Lavi, Z. Granot, S. Porat, L.H. Philipson, K.C. Herold, T.R. Bhatti, C. Stanley, F.M. Ashcroft, P. In’t Veld, A. Saada, M.A. Magnuson, B. Glaser, Y. Dor, Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in beta cells. Cell Metab. 19, 109–121 (2014)CrossRefPubMedGoogle Scholar
- 48.D.A. Cunha, M. Igoillo-Esteve, E.N. Gurzov, C.M. Germano, N. Naamane, I. Marhfour, M. Fukaya, J.M. Vanderwinden, C. Gysemans, C. Mathieu, L. Marselli, P. Marchetti, H.P. Harding, D. Ron, D.L. Eizirik, M. Cnop, Death protein 5 and p53-upregulated modulator of apoptosis mediate the endoplasmic reticulum stress-mitochondrial dialog triggering lipotoxic rodent and human beta-cell apoptosis. Diabetes 61, 2763–2775 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
- 50.C. Evans-Molina, R.D. Robbins, T. Kono, S.A. Tersey, G.L. Vestermark, C.S. Nunemaker, J.C. Garmey, T.G. Deering, S.R. Keller, B. Maier, R.G. Mirmira, Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure. Mol. Cell. Biol. 29, 2053–2067 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
- 51.K.K. Brown, B.R. Henke, S.G. Blanchard, J.E. Cobb, R. Mook, I. Kaldor, S.A. Kliewer, J.M. Lehmann, J.M. Lenhard, W.W. Harrington, P.J. Novak, W. Faison, J.G. Binz, M.A. Hashim, W.O. Oliver, H.R. Brown, D.J. Parks, K.D. Plunket, W.Q. Tong, J.A. Menius, K. Adkison, S.A. Noble, T.M. Willson, A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48, 1415–1424 (1999)CrossRefPubMedGoogle Scholar